Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.

Hernandez C, Arasanz H, Chocarro L, Bocanegra A, Zuazo M, Fernandez-Hinojal G, Blanco E, Vera R, Escors D, Kochan G.

Int J Mol Sci. 2020 Mar 31;21(7). pii: E2411. doi: 10.3390/ijms21072411. Review.

PMID:
32244396
2.

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics.

Arasanz H, Zuazo M, Bocanegra A, Gato M, Martínez-Aguillo M, Morilla I, Fernández G, Hernández B, López P, Alberdi N, Hernández C, Chocarro L, Teijeira L, Vera R, Kochan G, Escors D.

Cancers (Basel). 2020 Feb 4;12(2). pii: E344. doi: 10.3390/cancers12020344.

3.

Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.

Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D.

EMBO Mol Med. 2019 Jul;11(7):e10293. doi: 10.15252/emmm.201910293. Epub 2019 Jun 6.

4.

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.

Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G.

Int J Mol Sci. 2019 Apr 2;20(7). pii: E1631. doi: 10.3390/ijms20071631.

5.

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies.

Arasanz H, Zuazo M, Vera R, Kochan G, Escors D.

Lung Cancer Manag. 2018 Dec 20;7(3):LMT07. doi: 10.2217/lmt-2018-0014. eCollection 2018 Nov. No abstract available.

6.

The intracellular signalosome of PD-L1 in cancer cells.

Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G.

Signal Transduct Target Ther. 2018 Sep 28;3:26. doi: 10.1038/s41392-018-0022-9. eCollection 2018. Review.

7.

Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography.

Ibáñez-Vea M, Huang H, Martínez de Morentin X, Pérez E, Gato M, Zuazo M, Arasanz H, Fernández-Irigoyen J, Santamaría E, Fernandez-Hinojal G, Larsen MR, Escors D, Kochan G.

J Proteome Res. 2018 Mar 2;17(3):1172-1182. doi: 10.1021/acs.jproteome.7b00812. Epub 2018 Jan 25.

PMID:
29338241
8.

Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.

Zuazo M, Gato-Cañas M, Llorente N, Ibañez-Vea M, Arasanz H, Kochan G, Escors D.

Ann Transl Med. 2017 Oct;5(19):385. doi: 10.21037/atm.2017.06.11. Review.

9.

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.

Ibáñez-Vea M, Zuazo M, Gato M, Arasanz H, Fernández-Hinojal G, Escors D, Kochan G.

Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):113-123. doi: 10.1007/s00005-017-0492-4. Epub 2017 Oct 14. Review.

PMID:
29032490
10.

PD1 signal transduction pathways in T cells.

Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G, Escors D.

Oncotarget. 2017 Apr 19;8(31):51936-51945. doi: 10.18632/oncotarget.17232. eCollection 2017 Aug 1. Review.

11.

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, Wellbrock C, Llopiz D, Ruiz M, Sarobe P, Breckpot K, Kochan G, Escors D.

Cell Rep. 2017 Aug 22;20(8):1818-1829. doi: 10.1016/j.celrep.2017.07.075.

12.

Immunotherapy in malignant melanoma: recent approaches and new perspectives.

Arasanz H, Lacalle A, Lecumberri MJ, de Lascoiti ÁF, Blanco-Luquin I, GatoCañas M, Pérez-Ricarte L, Zuazo M, Kochan G, Escors D.

Melanoma Manag. 2017 Mar;4(1):39-48. doi: 10.2217/mmt-2016-0019. Epub 2017 Mar 1. Review.

13.

Novel immunotherapies for the treatment of melanoma.

Gato-Cañas M, Arasanz H, Blanco-Luquin I, Glaría E, Arteta-Sanchez V, Kochan G, Escors D.

Immunotherapy. 2016 May;8(5):613-32. doi: 10.2217/imt-2015-0024. Review.

PMID:
27140413
14.

A core of kinase-regulated interactomes defines the neoplastic MDSC lineage.

Gato-Cañas M, Martinez de Morentin X, Blanco-Luquin I, Fernandez-Irigoyen J, Zudaire I, Liechtenstein T, Arasanz H, Lozano T, Casares N, Chaikuad A, Knapp S, Guerrero-Setas D, Escors D, Kochan G, Santamaría E.

Oncotarget. 2015 Sep 29;6(29):27160-75. doi: 10.18632/oncotarget.4746.

Supplemental Content

Loading ...
Support Center